Breast cancer type 2 susceptibility protein; Fanconi anemia group D1 protein; BRCA2; FACD; FANCD1

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG1,kappa

1847CT631.23.58

Mouse

This antibody is generated from a mouse immunized with a recombinant protein from human.

Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.

Maintain refrigerated at 2-8 degree C for up to 2 weeks. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Small volumes of anti-BRCA2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded HR complex containing RAD51C and which is thought to play a role in DNA repair by HR. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity. In concert with NPM1, regulates centrosome duplication. Interacts with the TREX-2 complex (transcription and export complex 2) subunits PCID2 and SHFM1/DSS1, and is required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability. Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination (PubMed:24896180).

Primary Antibodies; Cancer

Western Blot (WB), ELISA (EIA)

WB: 1:2000

Anti-BRCA2 at 1:2000 dilution + Recombinant protein

Lysates/proteins at 20ng per lane.

Secondary
Goat Anti-mouse IgG, (H+L), Peroxidase conjugated at 1/10000 dilution.

Predicted band size : 384 kDa

Blocking/Dilution buffer: 5% NFDM/TBST.

384202 Da

BRCA2, DNA repair associated

breast cancer type 2 susceptibility protein

Breast cancer type 2 susceptibility protein

FACD; FANCD1??[Similar Products]

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, Dec 2008]

BRCA2: involved in double-strand break repair and/or homologous recombination. May participate in S phase checkpoint activation. Interacts with RAD51 and DSS1. Interacts with ubiquitinated FANCD2. Interacts with PALB2, enables the recombinational repair and checkpoint functions. Interacts with WDR16. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer and may underlie susceptibility to uveal melanoma.

Protein type: DNA repair, damage; Nuclear receptor co-regulator; Tumor suppressor

Chromosomal Location of Human Ortholog: 13q13.1

Cellular Component: BRCA2-MAGE-D1 complex; centrosome; cytoplasm; lateral element; nuclear chromosome, telomeric region; nucleoplasm; nucleus; protein complex; secretory granule

Molecular Function: gamma-tubulin binding; H3 histone acetyltransferase activity; H4 histone acetyltransferase activity; histone acetyltransferase activity; protease binding; protein binding; protein C-terminus binding; single-stranded DNA binding

Biological Process: centrosome duplication; cytokinesis; DNA synthesis during DNA repair; double-strand break repair; double-strand break repair via homologous recombination; negative regulation of mammary gland epithelial cell proliferation; nucleotide-excision repair; positive regulation of transcription, DNA-dependent; strand displacement

Disease: Breast Cancer; Breast-ovarian Cancer, Familial, Susceptibility To, 2; Fanconi Anemia, Complementation Group D1; Glioma Susceptibility 3; Medulloblastoma; Pancreatic Cancer, Susceptibility To, 2; Prostate Cancer; Tracheoesophageal Fistula With Or Without Esophageal Atresia; Wilms Tumor 1

Wooster R.,et al.Nature 378:789-792 (1995). Tavtigian S.V.,et al.Nat. Genet. 12:333-337 (1996). Dunham A.,et al.Nature 428:522-528 (2004). Ozcelik H.,et al.Nat. Genet. 16:17-18 (1997). Hussain S.,et al.Hum. Mol. Genet. 13:1241-1248 (2004).

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.